Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360568 · ClinicalTrials.gov registry record · Phase 3
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
A Phase 3 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT00360568 is a Phase 3 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 62 participants.
The verdict
NCT00360568, a Phase 3 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
Long term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.
Interventions
- DEVICE CADD-Legacy® 1400 ambulatory infusion pump
- DRUG Levodopa-carbidopa intestinal gel
- DEVICE PEG tube
- DEVICE J-tube
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00360568
The ClinicalTrials.gov registry entry for NCT00360568 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CADD-Legacy® 1400 ambulatory infusion pump is the first listed.
NCT00360568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00360568 about?
NCT00360568 is a clinical study titled "Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects". Long term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.
What is the current status of trial NCT00360568?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2009-06. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00360568?
The interventions under investigation include: CADD-Legacy® 1400 ambulatory infusion pump (DEVICE), Levodopa-carbidopa intestinal gel (DRUG), PEG tube (DEVICE), J-tube (DEVICE).
Who is sponsoring clinical trial NCT00360568?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.